Inhibrx Biosciences stock: Ozekibart posts 62.7% response rate
Published on 11/19/2026 at 03:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSOzekibart data reaches CTOS
- Inhibrx reported updated clinical findings from a Phase 1/2 study in relapsed or refractory Ewing sarcoma.
- The company plans to present the Ewing sarcoma poster at the CTOS 2026 Annual Meeting on Thursday, November 19.
- Ozekibart remains an investigational therapy as Inhibrx advances its oncology pipeline.
Inhibrx Biosciences announced updated clinical data for ozekibart, also known as INBRX-109, in relapsed or refractory Ewing sarcoma on Tuesday, November 17, 2026. The company said the findings will be presented at the Connective Tissue Oncology Society 2026 Annual Meeting on Thursday, November 19.
According to the Inhibrx announcement, the Phase 1/2 expansion study evaluated ozekibart combined with irinotecan and temozolomide in patients with relapsed or refractory disease. The September 18 data cutoff covered 60 treated patients, including nine adolescents, while 51 patients were response-evaluable.
Clinical results support next presentation
The combination produced a 62.7 percent overall response rate, including two complete responses and 30 partial responses. Disease control reached 86.3 percent after 12 additional patients achieved stable disease. Median progression-free survival was 6.0 months, with durable clinical benefit lasting more than six months in 18 patients.
Inhibrx said the safety profile remained acceptable and manageable, consistent with known toxicities from the chemotherapy combination and DR5 agonism. The company also said there was no evidence of unexpected cumulative hepatotoxicity. The results are interim clinical findings and do not establish regulatory approval or commercial availability of ozekibart for Ewing sarcoma.
The next visible catalyst is the CTOS presentation in Seoul. The poster is scheduled for the session on Thursday, November 19, while a separate ozekibart presentation in conventional chondrosarcoma is scheduled for Friday, November 20.
Pipeline-focused biotechnology company
Inhibrx Biosciences is a La Jolla, California-based clinical-stage biopharmaceutical company developing biologic therapeutic candidates. Its pipeline includes ozekibart and ordastobart, also known as INBRX-106, using multivalent protein-engineering formats. The company focuses on oncology programs, including Ewing sarcoma, chondrosarcoma, head and neck cancer, and non-small-cell lung cancer.
Inhibrx Biosciences at a glance
- Company: Inhibrx Biosciences, Inc.
- ISIN: US45720N1037
- Ticker: INBX
- Exchange: Nasdaq
- Business: Clinical-stage biopharmaceutical development
Inhibrx Biosciences operates in the US biotechnology market. Investors can follow broader US equities through the S&P 500 market environment.
